Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg

NCT01127620 is registered in ClinicalTrials.gov with Faes Farma, S.A. as lead sponsor.

NCT NCT01127620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01127620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg
Lead sponsor
Faes Farma, S.A.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2004
Completion date
November 30, 2006
Enrollment
650 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

perennial allergic rhinitis